CARA: חוב כולל להון Cara Therapeutics

Cara Therapeutics, Inc. (CARA) is developing a portfolio of treatments to combat chronic pruritus and neuropathic pain. However, the current ecosystem of drugs for renal patients is experiencing a crisis: partners have departed due to clinical failures, and new research has been halted. This chart illustrating the market price movement for the total debt-to-equity ratio shows 0.02, while the company is implementing ESG standards to reduce hazardous waste.

This ratio measures the proportion of borrowed funds relative to equity, determining the degree of financial leverage and the issuer's overall solvency. Given the high risks associated with clinical trials at Cara Therapeutics, Inc. (CARA), the current leverage ratio (total debt-to-equity) serves as an indicator of the company's ability to weather potential market failures without the threat of bankruptcy, where a decrease in this value confirms growing business autonomy.